ASIA PACIFIC ALOPECIA TREATMENT MARKET ANALYSIS

Asia Pacific Alopecia Treatment MarketSize and Trends

Asia Pacific Alopecia Treatment Market is estimated to be valued at US$ 2,477.0 million in 2023 and is expected to exhibit a CAGR of 6.8% during the forecast period (2023-2030).

Figure 1. Asia Pacific Alopecia Treatment Market Share (%), By Treatment Type, 2023

Asia Pacific Alopecia Treatment Market– Drivers

Increasing Research and Development Activities in Alopecia Treatment

Increasing Research and development by key market players is expected to drive growth of Asia Pacific alopecia treatment market over the forecast period.  For instance, Aeterna Health on February 28, 2023 stated hair regrowth treatment combines traditional and cutting-edge technology, mainly adipose-derived cells, to provide the best results for our patients. The treatments have the ability to self-renew and differentiate into various types of cells, making them a potential therapy for promoting hair growth. Cell therapy involves extracting cells from a patient’s adipose tissue, then culturing these cells in a laboratory before injecting them into the patient’s scalp.These cells can stimulate hair follicle growth, promote hair growth cycles, and improve hair quality and density. This treatment method is more effective than traditional drug therapies as it can promote scalp blood circulation, increase hair follicle nutrient supply, and thereby promote healthy hair growth.

Figure 2. Asia Pacific Alopecia Treatment Market Share (%), By Country, 2023

Asia Pacific Alopecia Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding transportation of drugs from one place to another.

COVID 19 had negative impact on the Asia Pacific alopecia treatment market.  For instance, an article published by National Center for Biotechnology Information on May 8, 2022 explained 57 patients participated in which the majority (84.2%) of the participants had mild anxiety assessed by corona disease anxiety scale. Two patients had got infected with COVID-19. Twenty-one participants experienced hair loss progression. Hair loss progression correlated with drug dose reduction although it did not influence by the level of anxiety evaluated by the  corona disease anxiety scale anxiety perceived by severe Alopecia Areata patients about COVID-19 is mild; however, many experience hair loss progressions owing to their drug dose reduction.

Asia Pacific Alopecia Treatment Market Segmentation:

Asia Pacific alopecia treatment market report is segmented into Treatment Type, by Disease Indications, By End User and by Region.

Based on Treatment Type, the Asia Pacific alopecia treatment market is segmented into Topical Drugs, Oral Drugs, Injectables, Hair Transplant Services, and Low-Level Laser Therapy. Out of which, Oral Drugs segment is expected to dominate the market due to increasing launch of medicines.

Based on Disease Indication, the Asia Pacific alopecia treatment market is segmented into Alopecia Areata, Alopecia Totalis, and Alopecia Universalis. Among these, Alopecia Areata segment is expected to dominate the market over the forecast period, owing to increasing research activities in companies.

Based on End User, the Asia Pacific alopecia treatment market is segmented into Hospitals, Dermatologic and Trichology Clinics, Home care settings, Aesthetic Clinics. Among these, Dermatologic and Trichology Clinics segment is expected to dominate the market due to increase in the treatment and advanced technologies in clinics.

Based on Country, the Asia Pacific alopecia treatment market is segmented into China, Japan, Australia, New Zealand, Malaysia, India, Singapore, Vietnam, Philippines, and Rest of APAC. Among these, China is expected to dominate the market over forecast period due to increased research and development activities.

Among all segmentation, the treatment type segment has the highest potential due to increasing  product approvals by the regulatory authorities. For instance, on June 23, 2023, Pfizer Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved LITFULO (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata. The approved recommended dose for LITFULO is 50 mg. It is the first and only treatment approved by the FDA for adolescents (12+) with severe alopecia areata.